Abstract
It is well known clinically that advanced, bulky visceral metastatic disease is generally much less responsive to most anti-cancer therapies, compared to microscopic metastatic disease. This problem is exacerbated when treating cancers that have been previously exposed to multiple lines of therapy, and which have acquired a ‘refractory–phenotype. However, mimicking such clinical treatment situations in preclinical mouse models involving the testing of new or existing cancer therapies is extremely rare. Treatment of ‘metastasis– in retrospect, usually involves minimal residual disease and therapy naïve tumors. This could account in many instances for the failure to reproduce highly encouraging preclinical results in subsequent phase I or phase II clinical trials. To that end, we have embarked on an experimental program designed to develop models of advanced, visceral metastatic disease, in some cases involving tumors previously exposed to various therapies. The strategy first involves the orthotopic transplantation of a human cancer cell line, such as breast cancer cell line, into the mammary fat pads of immune deficient mice, followed by surgical resection of the resultant primary tumors that develops. Recovery of distant macroscopic metastases, usually in the lungs, is then undertaken, which can take up to 4 months to visibly form. Cell lines are established from such metastases and the process of orthotopic transplantation, surgical resection, and recovery of distant metastases is undertaken, at least one more time. Using such an approach highly metastatically aggressive variant sublines can be obtained, provided they are once again injected into an orthotopic site and the primary tumors removed by surgery. By waiting sufficient time after removal of the primary tumors, about only 1 month, mice with extensive metastatic disease in sites such as the lungs, liver, and lymph nodes can be obtained. An example of therapy being initiated in an advanced stage of such disease development is illustrated. Metastases that eventually stop responding to a particular therapy can be removed as a source of variant cell lines which have both ‘refractory–and highly metastatic phenotypes. Such models may provide a more accurate picture of the potential responsiveness to an experimental therapy so that a high degree of responsiveness observed could be a factor in deciding whether to move a particular therapy forward into phase I/phase II clinical trial evaluation. An example of this is illustrated using doublet metronomic low-dose chemotherapy for the treatment of advanced metastatic breast cancer, using two conventional chemotherapy drugs, namely, cyclophosphamide and UFT, a 5-FU oral prodrug.
Similar content being viewed by others
References
Sharpless, N. E., & DePinho, R. A. (2006). The mighty mouse: Genetically engineered mouse models in cancer drug development. Nature Reviews Drug Discovery, 5, 741–54.
Kelland, L. R. (2004). “Of mice and men– Values and liabilities of the athymic nude mouse model in anticancer drug development. European Journal of Cancer, 40, 827–36.
Kamb, A. (2005). What’s wrong with our cancer models? Nature Reviews Drug Discovery, 4, 161–65.
Kung, A. L. (2007). Practices and pitfalls of mouse cancer models in drug discovery. Advances in Cancer Research, 96, 191–12.
Olive, K. P., & Tuveson, D. A. (2006). The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clinical Cancer Research, 12, 5277–287.
Becher, O. J., & Holland, E. C. (2006). Genetically engineered models have advantages over xenografts for preclinical studies. Cancer Research, 66, 3355–358.
Kerbel, R. S. (2003). Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: Better than commonly perceived—but they can be improved. Cancer Biology & Therapy, 2, 108–13.
Sausville, E. A., & Burger, A. M. (2006). Contributions of human tumor xenografts to anticancer drug development. Cancer Research, 66, 3351–354, discussion.
Hoffman, R. M. (2005). Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy. Methods in Molecular Medicine, 111, 297–22.
Inaba, M., Tashiro, T., Kobayashi, T., Sakurai, Y., Maruo, K., Ohnishi, Y., et al. (1988). Responsiveness of human gastric tumors implanted in nude mice to clinically equivalent doses of various antitumor agents. Japanese Journal of Cancer Research, 79, 517–22.
Inaba, M., Kobayashi, T., Tashiro, T., Sakurai, Y., Maruo, K., Ohnishi, Y., et al. (1989). Evaluation of antitumor activity in a human breast tumor/nude mouse model with a special emphasis on treatment dose. Cancer, 64, 1577–582.
Bibby, M. C. (2004). Orthotopic models of cancer for preclinical drug evaluation: advantages and disadavantages. European Journal of Cancer, 40, 852–57.
Chen, H. X., Mooney, M., Boron, M., Vena, D., Mosby, K., Grochow, L., et al. (2006). Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: An NCI Treatment Referral Center Trial TRC-0301. Journal of Clinical Oncology, 24, 3354–360.
Tripathy, D. (2007). Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: Underlying rationale and results of clinical trials. Oncologist, 12, 375–89.
Fidler, I. J. (1973). Selection of successive cell lines for metastasis. Nature New Biology, 242, 148–49.
Killion, J. J., Radinsky, R., & Fidler, I. J. (1998). Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer and Metastasis Reviews, 17, 279–84.
Munoz, R., Man, S., Shaked, Y., Lee, C. R., Wong, J., Francia, G., et al. (2006). Highly efficacious non-toxic treatment for advanced metastatic breast cancer using combination UFT-cyclophosphamide metronomic chemotherapy. Cancer Research, 66, 3386–391.
Stephenson, R. A., Dinney, C. P., Gohji, K., Ordonez, N. G., Killion, J. J., & Fidler, I. J. (1992). Metastatic model for human prostate cancer using orthotopic implantation in nude mice. Journal of the National Cancer Institute, 84, 951–57.
Dinney, C. P., Babkowski, R. C., Antelo, M., Perrotte, P., Liebert, M., Zhang H. Z., et al. (1998). Relationship among cystectomy, microvessel density and prognosis in stage T1 transitional cell carcinoma of the bladder. Journal of Urology, 160, 1285–290.
Fidler, I. J. (1991). Orthotopic implantation of human colon carcinomas into nude mice provides a valuable model for the biology and therapy of metastasis. Cancer and Metastasis Reviews, 10, 229–43.
Chen, C., Parangi, S., Tolentino, M. J., & Folkman, J. (1995). A strategy to discover circulating angiogenesis inhibitors generated by human tumors. Cancer Research, 55, 4230–233.
O’Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., et al. (1994). Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79, 315–28.
Browder, T., Butterfield, C. E., Kraling, B. M., Marshall, B., O’Reilly, M. S., & Folkman, J. (2000). Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Research, 60, 1878–886.
Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., et al. (2000). Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. Journal of Clinical Investigation, 105, R15’R24.
Hanahan, D., Bergers, G., & Bergsland, E. (2000). Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. Journal of Clinical Investigation, 105, 1045–047.
Kerbel, R. S., & Kamen, B. A. (2004). Antiangiogenic basis of low-dose metronomic chemotherapy. Nature Reviews. Cancer, 4, 423–36.
Shaked, Y., Emmengger, U., Man, S., Cervi, D., Bertolini, F., Ben-David, Y., et al. (2005). The optimal biological dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood, 106, 3058–061.
Prewett, M., Huber, J., Li, Y., Santiago, A., O’Connor, W., King, K., et al. (1999). Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Research, 59, 5209–218.
Fidler, I. J., & Ellis, L. M. (2000). Chemotherapeutic drugs-more really is not better. Nature Medicine, 6, 500–02.
Man, S., Bocci, G., Francia, G., Green S. K., Jothy, S., Hanahan, D., et al. (2002). Antitumor and anti-angiogenic effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Research, 62, 2731–735.
Kato, H., Ichinose, Y., Ohta, M., Hata, E., Tsubota, N., Tada, H., et al; Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy (2004). A randomized trial of adjuvant chemotherapy with uracil’tegafur for adenocarcinoma of the lung. New England Journal of Medicine, 350, 1713–721.
Shaked, Y., Bertolini, F., Man, S., Rogers, M. S., Cervi, D., Foutz T., et al. (2005). Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell, 7, 101–11.
Nio, Y., Iguchi, C., Kodama, H., Itakura, M., Hashimoto, K., Koike M., et al. (2007). Cyclophosphamide augments the anti-tumor efficacy of uracil and tegafur by inhibiting dihydropyrimidine dehydrogenase. Oncology Reports, 17, 153–59.
Cornil, I., Man, S., Fernandez, B., & Kerbel, R. S. (1989). Enhanced tumorigenicity, melanogenesis, and metastases of a human malignant melanoma after subdermal implantation in nude mice. Journal of the National Cancer Institute, 81, 938–44.
Palmieri, D., Chambers, A. F., Felding-Habermann, B., Huang, S., & Steeg, P. S. (2007). The biology of metastasis to a sanctuary site. Clinical Cancer Research, 13, 1656–662.
Cranmer, L. D., Trevor, K. T., Bandlamuri, S., & Hersh, E. M. (2005). Rodent models of brain metastasis in melanoma. Melanoma Research, 15, 325–56.
Kerbel, R. S. (2006). Antiangiogenic therapy: A universal chemosensitization strategy for cancer? Science, 312, 1171–175.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Man, S., Munoz, R. & Kerbel, R.S. On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing. Cancer Metastasis Rev 26, 737–747 (2007). https://doi.org/10.1007/s10555-007-9087-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10555-007-9087-6